Top Tech Companies (60)
We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed loop models of care. To learn more about our mission to deliver #PrecisionCareForAll, please visit: www.closedloopmedicine.com
Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research, influence and information. Nearly one in two of us will get cancer in our lifetime, but we’re finding new ways to outsmart it, so that more people can live longer, better lives free from the fear of cancer. We carry out scientific research to help prevent, diagnose and treat cancer and our groundbreaking work, funded almost entirely by the general public, will ensure that millions more people survive. Together we are beating cancer. Registered charity No. 1089464
Accessible AI for all drug discovery researchers. At Ro5, we provide the benefits of AI and digital transformation through a software platform that empowers our clients to focus on what they’re best at - drug discovery. Ro5 makes AI accessible to the industry by providing the expertise, infrastructure, software, models, and data necessary for digital transformation. Our software products are developed for real-world challenges, solving the unique problems faced by our clients that focus on R&D. Our solutions augment researcher’s workflows, enable data-driven decisions, and accelerate research. Ro5 has 5 years of experience providing services and software for pharmaceutical companies and CROs in projects spanning the entire drug discovery and development pipeline. Ro5 has a growing portfolio of scientific publications with 3 papers and 13 awarded patents. Contact us to learn more about how Ro5’s platforms and digital transformation could help achieve your and your organization’s research goals.
Acurable is a fast-growing, venture backed MedTech start-up with offices in London and Seville. We create accurate and user-friendly wearable medical devices intended to be used by patients at home. Our award-winning, patented technology enables for the first time the automated diagnosis and management of respiratory conditions. It is the product of more than 10 years’ research at Imperial College London by Acurable’s founder, Professor Esther Rodriguez Villegas, and has been recognised as a breakthrough in respiratory medicine, winning some of the most respected awards in the industry, among them an XPrize and several Innovate UK grants. It has also featured in national and international media, including earlier this year in the BBC Horizon documentary How to Sleep Well with Michael Mosley. In 2020 our first product, AcuPebble SA100, became the first medical device in the world to obtain the CE mark for the automated diagnosis of obstructive sleep apnoea at home, and a few months later the product gained FDA clearance for home sleep apnoea testing in the US. AcuPebble SA100 is now in use within healthcare organisations across the UK and Europe, and will be launching in the USA in the coming months. At the same time we continue our research to develop new products that will fundamentally improve the lives of millions of people suffering from serious chronic conditions such as COPD, Asthma and Epilepsy.
Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
H.E.L Group’s mission is to work together with chemistry, safety and biotechnology experts to engineer and unleash the full potential of the scientific community. To this end, H.E.L develops and manufactures innovative scientific instruments and software designed to optimize the efficiency, safety and productivity of key processes in chemistry and biology applications. The H.E.L team of 70 includes highly skilled process and software engineers, based at their extensive research and manufacturing facilities in the UK, as well as sales and support offices around the world. H.E.L has a long history of solving complex challenges for customers. For more than 30 years the Company has worked with businesses and laboratories globally, providing proprietary automated solutions for the pharma, biotechnology, chemical, battery and petrochemical sectors. Following significant growth, and with annual revenues exceeding £10 million, the Company is extending the reach of its products to support and enable R&D and process optimization further across the US, China and India.
For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing plants, 8 R&D centres and c8,800 employees worldwide. *As of February 2023 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at PV@hikma.com
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 24 million patients around the world in 2021 and generated €505 million in net product sales, a growth of 10% over 2020. Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world. In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Helping independent pharmacies to transform into diagnostic centres.
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.
Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
Virtual Science AI is reimagining how the Healthcare Industry generates external stakeholder insights. These insights are delivered via our unique and ground breaking artificial Intelligence platform, and are faster, clearer and more actionable. AI-driven analytics created through interactive data analysis, including sentiment analysis reports, ensure immediate actionable insights. The engagement of HCP's, patient experts, payers and other stakeholders provides end-to-end advisory services powered by our 24/7 engagement platform. Through asynchronized working, our clients determine key strategic insights that refine scientific and commercial messaging. The generation of these insights shapes the building of robust strategies that are co-created with HCP's, patients, payers and communities ensuring successful market dynamics and improving long-term patient care. The capitalisation of the company via Venture Capital and Health Tech funds is a reflection of the dynamic, exciting and innovative nature of our mission. Contact us now via our website, as we would love to demonstrate the significant benefits that our AI software platform will bring to your insight generation. http://www.virtualscienceai.com Take your insight generation to the next dimension
Pharmacierge is the digital e-prescribing service chosen by private clinicians to deliver medication to their patients throughout the UK and worldwide. Clinicians create and transfer e-prescriptions to our pharmacy near London's Harley Street, for free delivery to their patients*. GMC clinicians in private practice can register for our e-prescription platform here: www.pharmacierge.com/register. Alternatively call 0207 637 9755 or email us via www.pharmacierge.com/contact Key features of our service: - Free for clinicians and clinics - E-prescribe securely for patients within a few clicks - E-prescriptions do not require original hard copies sent by post - Save time coordinating with pharmacies - Patients receive a phone call and/or SMS requesting secure payment - Secure compatibility with all practice systems - Discreet packaging and tracked delivery - Competitively priced medication - Clinician reviews: www.pharmacierge.com/clinicians Pharmacierge is located next to the Royal Society of Medicine, at the heart of London's Harley Street Medical Area. We maintain the highest standards of patient care as expected by elite clinicians throughout the private pathway. *Free Tracked Delivery Nationwide
ENBIOSIS Biosciences reaches deep into your inner world with microbiome analysis and offers you the key for a sustainable and healthy life
